On the close of 05/17/2017 ACADIA Pharmaceuticals Inc. "(ACAD) is Harvey Capital Management Inc.'s 8th Largest Position" was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. The stock witnessed -16.58% declines, -31.44% declines and -6.88% declines for the 1-month, 3-month and 6-month period, respectively. Institutional investors and hedge funds own 98.25% of the company's stock.
Stock of ACADIA Pharmaceuticals Inc.
A number of other large investors have also modified their holdings of ACAD. Russell Investments Group Ltd. acquired a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at approximately $145,000. BlackRock Inc. now owns 5,433,209 shares of the biopharmaceutical company's stock worth $186,791,000 after buying an additional 5,334,832 shares during the last quarter. Elliott Management Corp bought a new position in shares of ACADIA Pharmaceuticals during the first quarter worth about $26,726,000. Insiders own 21.65% of the company's stock. Spot Trading L.L.C acquired a new stake in shares of ACADIA Pharmaceuticals during the third quarter valued at approximately $245,000. Rhumbline Advisers now owns 108,683 shares of the biopharmaceutical company's stock worth $3,457,000 after buying an additional 9,653 shares in the last quarter.
According to Zacks, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders". (NASDAQ:ACAD) opened at 27.06 on Thursday. However, the company's most recent quarter increase of 3.8% looks unattractive.
Reporters barred from Kushner Companies' visa-for-investment event in China
Almost 90 per cent of EB-5 visas were issued to Chinese nationals in 2014, when the programme reached its quota of 10,000 visas. On Sunday Meyer was introduced in Chinese to investors as a representative of "a famed celebrity investment family".
ACADIA Pharmaceuticals Inc. has a 50 day moving average of 32.18 and a 200 day moving average of 31.92. ACADIA Pharmaceuticals Inc. has a 52 week low of $20.68 and a 52 week high of $42.49.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($0.73) by $0.01. ACADIA Pharmaceuticals had a negative return on equity of 58.46% and a negative net margin of 4,427.79%. The business had revenue of $15.30 million for the quarter, compared to the consensus estimate of $15.17 million. In terms of leverage and liquidity, one point was given for a lower ratio of long term debt in the current period compared to the previous year, one point was given for higher current ratio compared to the previous year, and one point if no new shares were issued in the last year. Equities analysts predict that ACADIA Pharmaceuticals will post ($2.85) earnings per share for the current fiscal year.
WARNING: This news story was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this piece on another website, it was stolen and reposted in violation of U.S. and global copyright legislation. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2017/05/18/analysts-expect-acadia-pharmaceuticals-inc-acad-will-announce-quarterly-sales-of-13-82-million-updated-updated-updated.html. (NASDAQ:ACAD) shares have performed -5.17%. HC Wainwright reiterated a buy rating on shares of ACADIA Pharmaceuticals in a research report on Wednesday, May 10th. Vetr downgraded ACADIA Pharmaceuticals from a "strong-buy" rating to a "buy" rating and set a $37.64 price objective on the stock.in a report on Tuesday, January 31st.
10/07/2013 - Ned Davis Research began new coverage on ACADIA Pharmaceuticals Inc. giving the company a "neutral" rating. They issued a "buy" rating and a $48.00 price target for the company. Zacks Investment Research upgraded shares of ACADIA Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday, May 12th. Needham & Company LLC restated a "buy" rating and set a $49.00 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday, April 5th.
- Macron Wins French Election
- Conservatives record early gains in United Kingdom local elections
- Alaska governor calls for special session to resolve deficit
- Liverpool hold talks with Manchester United and Chelsea target Tiemoue Bakayoko
- Times Square suspect was Navy exit, alcohol, plagued, sources say
- Paytm Now US$7 Bn Strong; Gains US$1.4 Bn from SoftBank
- Several injured, 1 dead after speeding vehicle drives into Times
- Car drives wrong way in Times Square and hits crowds; 1 dead
- Shadow Brokers Threaten To Unleash More Hacking Tools
- Macron reçoit le secrétaire général de l'ONU Guterres — France